SAGE-718 and NMDA Receptors

Sage Therapeutics Announces Planned Progression of SAGE-718 to Phase 2 in Huntington's Disease and Presentations at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP)

Retrieved on: 
Tuesday, December 10, 2019
Biotechnology, Mental health, Health, Pharmaceutical, Clinical trials, Neuropharmacology, Clinical pharmacology, Behavioral neuroscience, Neuropsychology, Neuropsychopharmacology, Psychopharmacology, Tolerability, Branches of biology, SAGE-718 and NMDA Receptors, Sage Therapeutics

The planned progression of SAGE-718 is based on results from Phase 1 studies evaluating the safety and tolerability of SAGE-718, including an open-label cohort of patients with HD.

Key Points: 
  • The planned progression of SAGE-718 is based on results from Phase 1 studies evaluating the safety and tolerability of SAGE-718, including an open-label cohort of patients with HD.
  • In the study, SAGE-718 was well tolerated, with no serious adverse events or adverse events leading to treatment discontinuation.
  • These results are comparable to improvements in measures of executive function observed in an earlier Phase 1 cohort of individuals without HD.
  • In addition, the Company is presenting data from three other non-clinical and Phase 1 studies with SAGE-718 at the 58th Annual Meeting of the American College of Neuropsychopharmacology (ACNP).